Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2009 1
2010 2
2011 1
2013 1
2014 1
2015 3
2016 2
2017 4
2018 9
2019 13
2020 15
2021 17
2022 23
2023 22
2024 19
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Cannabis-Based Products for Chronic Pain : A Systematic Review.
McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. McDonagh MS, et al. Ann Intern Med. 2022 Aug;175(8):1143-1153. doi: 10.7326/M21-4520. Epub 2022 Jun 7. Ann Intern Med. 2022. PMID: 35667066 Free article.
LIMITATION: Variation in interventions; lack of study details, including unclear availability in the United States; and inadequate evidence for some products. CONCLUSION: Oral, synthetic cannabis products with high THC-to-CBD ratios and sublingual, extracted cannabis …
LIMITATION: Variation in interventions; lack of study details, including unclear availability in the United States; and inadequate evidence …
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K. Filippini G, et al. Cochrane Database Syst Rev. 2022 May 5;5(5):CD013444. doi: 10.1002/14651858.CD013444.pub2. Cochrane Database Syst Rev. 2022. PMID: 35510826 Free PMC article.
SELECTION CRITERIA: We included randomised parallel or cross-over trials (RCTs) evaluating any cannabinoid (including herbal Cannabis, Cannabis flowers, plant-based cannabinoids, or synthetic cannabinoids) irrespective of dose, route, frequency, or duration of use f …
SELECTION CRITERIA: We included randomised parallel or cross-over trials (RCTs) evaluating any cannabinoid (including herbal Cannabis …
Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions.
Bell AD, MacCallum C, Margolese S, Walsh Z, Wright P, Daeninck PJ, Mandarino E, Lacasse G, Kaur Deol J, de Freitas L, St Pierre M, Belle-Isle L, Gagnon M, Bevan S, Sanchez T, Arlt S, Monahan-Ellison M, O'Hara J, Boivin M, Costiniuk C. Bell AD, et al. Cannabis Cannabinoid Res. 2024 Apr;9(2):669-687. doi: 10.1089/can.2021.0156. Epub 2023 Mar 27. Cannabis Cannabinoid Res. 2024. PMID: 36971587 Free PMC article.
Cannabidiol in canine epilepsy.
Potschka H, Bhatti SFM, Tipold A, McGrath S. Potschka H, et al. Vet J. 2022 Dec;290:105913. doi: 10.1016/j.tvjl.2022.105913. Epub 2022 Oct 6. Vet J. 2022. PMID: 36209995 Free article.
Assessing Cannabidiol as a Therapeutic Agent for Preventing and Alleviating Alzheimer's Disease Neurodegeneration.
Chen L, Sun Y, Li J, Liu S, Ding H, Wang G, Li X. Chen L, et al. Cells. 2023 Nov 21;12(23):2672. doi: 10.3390/cells12232672. Cells. 2023. PMID: 38067101 Free PMC article.
Neuroinflammation, which is central to AD's pathology, results in synaptic and neuronal damage, highlighting the importance of addressing inflammation and conserving neuronal integrity. Cannabidiol (CBD), derived from cannabis, is noted for its neuroprotective and anti-inf …
Neuroinflammation, which is central to AD's pathology, results in synaptic and neuronal damage, highlighting the importance of addressing in …
Cannabis Use and Sharing Practices Among Sexual Minority and Heterosexual Individuals During the COVID-19 Pandemic.
Assaf RD, Javanbakht M, Gorbach PM, Cooper ZD. Assaf RD, et al. LGBT Health. 2023 Oct;10(7):514-525. doi: 10.1089/lgbt.2022.0236. Epub 2023 May 26. LGBT Health. 2023. PMID: 37252794 Free PMC article.
Purpose: Cannabis behaviors during the COVID-19 pandemic among sexual minority (SM) individuals in the United States remain understudied. ...Conclusions: SM respondents were less likely to use cannabis with high frequency during the pandemic but more l …
Purpose: Cannabis behaviors during the COVID-19 pandemic among sexual minority (SM) individuals in the United States remain un …
Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment.
Stasiłowicz A, Tomala A, Podolak I, Cielecka-Piontek J. Stasiłowicz A, et al. Int J Mol Sci. 2021 Jan 14;22(2):778. doi: 10.3390/ijms22020778. Int J Mol Sci. 2021. PMID: 33466734 Free PMC article. Review.
Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. ...The synergism of action of phytochemicals present in Cannabis sp. raw material is also expressed in their increased bioavailabilit …
Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. …
Changes in health harms due to cannabis following legalisation of non-medical cannabis in Canada in context of cannabis commercialisation: A scoping review.
Myran DT, Imtiaz S, Konikoff L, Douglas L, Elton-Marshall T. Myran DT, et al. Drug Alcohol Rev. 2023 Feb;42(2):277-298. doi: 10.1111/dar.13546. Epub 2022 Sep 27. Drug Alcohol Rev. 2023. PMID: 36165188
ISSUE: On 17 October 2018, Canada legalised non-medical cannabis. Critically, the cannabis market in Canada has changed considerably since legalisation. ...APPROACH: Electronic searches were conducted to identify studies that compared changes in cannabis-rela …
ISSUE: On 17 October 2018, Canada legalised non-medical cannabis. Critically, the cannabis market in Canada has changed consid …
Pharmacotherapy for the Treatment of Cannabis Use Disorder: A Systematic Review.
Kondo KK, Morasco BJ, Nugent SM, Ayers CK, O'Neil ME, Freeman M, Kansagara D. Kondo KK, et al. Ann Intern Med. 2020 Mar 17;172(6):398-412. doi: 10.7326/M19-1105. Epub 2020 Mar 3. Ann Intern Med. 2020. PMID: 32120384
BACKGROUND: Cannabis use disorder (CUD) is a growing concern, and evidence-based data are needed to inform treatment options. ...Because of increasing access to and use of cannabis in the general population, along with a high prevalence of CUD among current canna …
BACKGROUND: Cannabis use disorder (CUD) is a growing concern, and evidence-based data are needed to inform treatment options. ...Beca …
120 results